AZ/Merck & Co's ovarian cancer drug gets wider US licence

AstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to be used in a wider group of ovarian cancer patients when combined with Roche’s

FDA approves new heart failure use for AZ's Farxiga

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fract

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class

AZ maintains 2020 guidance as Q1 sales grow despite pandemic

The ongoing pandemic will not affect AstraZeneca’s performance in 2020, the company has said after its first quarter results beat analysts’ expectations. 

AZ, Lilly join efforts to develop drugs for COVID-19

Tagrisso trial halted early after ‘overwhelming’ efficacy

A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results.